SCHEMBL1749110

SCHEMBL1749110

CN(C)C1CN(c2ccc(N)cc2)CC1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
ALDH1A1 P00352 5/20 0.41
GFER P55789 4/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 3/20 0.41
KMT2A Q03164 2/20 0.41
ADRA2C P18825 1/20 0.41
PTK2B Q14289 1/20 0.41
ESR2 Q92731 1/20 0.41
CASP6 P55212 1/20 0.39
HTT P42858 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 2/20 0.38
ALOX15 P16050 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749109 1.00 MAPT (0.41) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL1749111 1.00 MAPT (0.41) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL1749320 0.83 GFER (0.44) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL6709078 0.82 MAPT (0.48) MAPTALDH1A1GFERKDM4EGAA
Hydrochloric Acid SCHEMBL6712278 0.80 MAPT (0.52) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL6220961 0.78 MAPT (0.45) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL1750370 0.78 MAPT (0.39) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL189433 0.77 MAPT (0.47) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL6206883 0.76 GFER (0.38) MAPTALDH1A1GFERKDM4EGAA
SCHEMBL6206885 0.76 GFER (0.38) MAPTALDH1A1GFERKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 MAPT 4824/4885ALDH1A1 286/4885GFER 823/4885
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MAPT 4800/4885ALDH1A1 374/4885GFER 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.